Jia-Kang He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jia-Kang He has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chao Li
Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China
1 shared publication - Lianjun Gao
Department of Cardiology, Institute of Cardiovascular Diseases, The First Affiliated Hospital of Dalian Medical University
1 shared publication - Sheng-Xing Tang
Department of Cardiovascular Medicine, the First Affiliated Hospital of Wannan Medical College, Wuhu 241001, China
1 shared publication - Xiao Han
Institute of Cardio-Cerebrovascular Medicine, Central Hospital of Dalian University of Technology, Dalian, China
1 shared publication - Xiao-Hong Yu
Department of Cardiology First Affiliated Hospital of Dalian Medical University Dalian China
1 shared publication - Yun-Long Zhang
Department of Cardiology, Yijishan Hospital of Wannan Medical College, Wuhu, China
1 shared publication
Latest Publications
- Open Access
- 14 August 2025
- Published by Portland Press Ltd. in Clinical Science
- Vol. 139 (17) , 923-940
FAP deficiency attenuates T2DM-associated HFpEF by suppressing the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway
Heart failure with preserved ejection fraction (HFpEF) represents the initial phase of cardiac dysfunction associated with type 2 diabetes mellitus (T2DM). To date, the pathophysiological mechanisms underlying T2DM-induced HFpEF are complex and elusive. Fibroblast activation protein (FAP) is a prolyl-specific serine protease that its inhibition or vaccination has been shown to enhance cardiac repair following myocardial infarction (MI). However, the role and underlying molecular mechanisms by which abnormal FAP activity promotes the development of T2DM-induced HFpEF remain to be elucidated. In this study, the plasma activity and level of FAP were significantly higher in the T2DM with HFpEF group compared to the healthy control group. Moreover, plasma FAP activity and level were positively correlated with the likelihood of T2DM with HFpEF. To investigate the mechanistic involvement of FAP in the development of T2DM-associated HFpEF, a chronic T2DM mouse model was established. The results revealed that FAP KO significantly improved BNP level and E/A ratios compared to the WT T2DM group. Additionally, FAP KO and FAP inhibitor Talabostat alleviated myocardial inflammation, fibrosis, cardiomyocyte apoptosis, oxidative stress and energy metabolism dysfunction. Mechanistically, abnormal increase FAP triggered the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway, leading to the aforementioned pathological changes in T2DM-induced HFpEF. In contrast, FAP KO suppressed the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway and attenuated these pathological changes. Overall, these findings suggest that FAP may serve as a critical therapeutic target for T2DM-induced HFpEF.
- 14 August 2025
- Published by Portland Press Ltd. in Clinical Science
- Vol. 139 (17) , 923-940
Open AccessFAP deficiency attenuates T2DM-associated HFpEF by suppressing the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway
Heart failure with preserved ejection fraction (HFpEF) represents the initial phase of cardiac dysfunction associated with type 2 diabetes mellitus (T2DM). To date, the pathophysiological mechanisms underlying T2DM-induced HFpEF are complex and elusive. Fibroblast activation protein (FAP) is a prolyl-specific serine protease that its inhibition or vaccination has been shown to enhance cardiac repair following myocardial infarction (MI). However, the role and underlying molecular mechanisms by which abnormal FAP activity promotes the development of T2DM-induced HFpEF remain to be elucidated. In this study, the plasma activity and level of FAP were significantly higher in the T2DM with HFpEF group compared to the healthy control group. Moreover, plasma FAP activity and level were positively correlated with the likelihood of T2DM with HFpEF. To investigate the mechanistic involvement of FAP in the development of T2DM-associated HFpEF, a chronic T2DM mouse model was established. The results revealed that FAP KO significantly improved BNP level and E/A ratios compared to the WT T2DM group. Additionally, FAP KO and FAP inhibitor Talabostat alleviated myocardial inflammation, fibrosis, cardiomyocyte apoptosis, oxidative stress and energy metabolism dysfunction. Mechanistically, abnormal increase FAP triggered the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway, leading to the aforementioned pathological changes in T2DM-induced HFpEF. In contrast, FAP KO suppressed the CaMKIIδ-Calcineurin A-NFATc2 signaling pathway and attenuated these pathological changes. Overall, these findings suggest that FAP may serve as a critical therapeutic target for T2DM-induced HFpEF.